Clinical Trials Directory

Trials / Completed

CompletedNCT00401492

MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer

Phase II Study of Chemotherapy With Gemcitabine in Prolonged Infusion or With Schedules With Cisplatin in Non-small Cell Lung Cancer Elderly Patients

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
159 (actual)
Sponsor
National Cancer Institute, Naples · Academic / Other
Sex
All
Age
70 Years
Healthy volunteers
Not accepted

Summary

The main purpose of this study is to describe activity and toxicity of single-agent gemcitabine given as prolonged infusion, and of two 2-drug combinations containing cisplatin (cisplatin + vinorelbine, and cisplatin + gemcitabine) in the treatment of elderly patients with advanced non small cell lung cancer

Detailed description

The study design includes three parallel phase II studies, all with the same rules for patient selection and outcome assessment. In the two studies of cisplatin-based doublets, a dose-finding phase is planned, with subsequent cohorts of 6 patients treated with increasing doses of cisplatin (50-60-70 mg/m²). Following this phase, patients will be assigned to the three studies through a randomization procedure, to reduce selection biases. Arm A: gemcitabine: Gemcitabine 1200 mg/m2 intravenously in 2 hours (10 mg/m²/minute) on days 1 \& 8 of each cycle, every 21 days, for a maximum of 6 cycles. Arm B: cisplatin + vinorelbine: Vinorelbine 25 mg/m² on days 1 \& 8, followed by Cisplatin (50 or 60 or 70 mg/m²) on day 1 of each cycle, every 21 days, for a maximum of 6 cycles. Arm C: cisplatin + gemcitabine: Gemcitabine 1000 mg/m2,, on days 1 \& 8, followed by Cisplatin (50 or 60 or 70 mg/m²) on day 1 of each cycle, every 21 days, for a maximum of 6 cycles.

Conditions

Interventions

TypeNameDescription
DRUGgemcitabine prolonged continuous infusion
DRUGcisplatin
DRUGvinorelbine

Timeline

Start date
2002-06-01
Primary completion
2006-12-01
Completion
2007-04-01
First posted
2006-11-20
Last updated
2012-07-13

Source: ClinicalTrials.gov record NCT00401492. Inclusion in this directory is not an endorsement.